FIGURE LEGENDS

Supplemental Material, Figure 1. Effect of As $(0\sim10~\mu\text{M})$ on the cell viability in RA-induced differentiating Neuro-2a cells were treated with arsenic $(0, 0.625, 1.25, 2.5, 5, \text{ and } 10~\mu\text{M})$ for 48 h, and the viability of cells was determined by MTT. Each data point was the mean $\pm \text{S.E.}$ of three independent experiments. *p < 0.05, statistically significant difference from RA-treated cells.


Supplemental Material, Figure 2. (F) The expression of NF and MAP2 were determined by western blot and immunofluorescence staining.

Supplemental Material, Figure 3. Relative amount of expression of p-AMPK α (Thr172), p-AMPK β , and p-ACC in RA and combined treatment at each time point (Top panel), and relative fold increase of RA treatment compared with RA/As treatment (Bottom panel). The relative amounts of p-AMPK α (Thr172), p-AMPK β , and p-ACC were measured microdensitometrically and normalized to the expression of GAPDH. Each data point was the mean \pm S.E. of three independent experiments.


Supplemental Material, Figure 4. Relative amount of expression of p-LKB1 (Ser428) in RA and RA/As treatment at each time point (Top panel), and relative fold increase of RA treatment compared with RA/As treatment (Bottom panel). The relative amounts of p-LKB1 (Ser428) were measured microdensitometrically and normalized to the expression of GAPDH. Each data point was the mean \pm S.E. of three independent experiments.

Supplemental Material, Figure 5. Relative amount of p-LKB1 and LKB1 in the cytoplasm and nucleus. The relative amounts of p-LKB1 (Ser428) and LKB1 were measured microdensitometrically and normalized to the expression of GAPDH. Each data point was the mean ±S.E. of three independent experiments.


Supplemental Material, Figure 6. The expression of CaMKK β in RA and RA/As treatment at each time point. The expression of CaMKK β was determined with immunoblotting. The expression of GAPDH served as an internal loading control.




Supplemental Material, Figure 1




Supplemental Material, Figure 2




Supplemental Material, Figure 3



Supplemental Material, Figure 4



Supplemental Material, Figure 5



Supplemental Material, Figure 6